Effects of age and estrogen status on the skeletal IGF regulatory system
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Human marrow was obtained as material discarded during total hip replacement and was established in culture with phenol red-free α-MEM with 10% fetal bovine serum (FBS) and antibiotics. Insulin-like growth factor I (IGF-I) and its binding proteins were secreted by human marrow cells, in amounts that increased with time in culture. Western ligand blotting showed that insulin-like growth factor binding protein-3 (IGFBP-3) accounted for the majority (∼75%) of the secreted binding proteins. Evidence for marrow secretion of BP-3 protease was found by electrophoretic analysis of mixtures of radiolabeled IGFBP-3 and marrow-conditioned media. The amount of constitutive secretion of IGFBP-3 increased with age of the subject (r=0.97,p=0.0058). A notable exception was marrow from a postmenopausal women on estrogen replacement therapy (ERT) at the time of surgery; her marrow secreted 89.3 ng/mL after 14 d in vitro, only 38% of the IGFBP-3 that was secreted by cultures from two age-matched peers (208.8 and 285.2 ng/mL). This in vivo effect of estrogen was matched by an in vitro experiment in which 10−8 M 17-β estradiol suppressed IGFBP-3 to 60% of the constitutive level. In all cultures of marrow from postmenopausal women, IL-1β suppressed IGFBP-3 secretion to either undetectable levels or levels between 11% and 35% of control. Thus, human bone marrow cultures demonstrate components of the skeletal IGF regulatory system: IGF-I, IGF-binding proteins, and evidence of IGFBP-3 proteolysis. These results provide evidence of regulation by both systemic (age, estrogen status) and cytokine (IL-1β) factors.
- Jones, J. I. and Clemmons, D. R. (1995).Endocr. Rev. 16, 3–29. CrossRef
- Rosen, C. J., Donahue, L. R., and Hunter, S. J. (1994).Proc. Soc. Exp. Biol. Med. 206, 83–102.
- Breier, B. H., Gallagher, B. W., and Gluckman, P. D. (1991).Endocrinology 128, 247–357.
- Glowacki, J. (1995).Calcif. Tissue Int. 56, S50,51.
- Cheleuitte, D., Mizuno, S., Reichel, H., and Glowacki, J. (1995).J. Bone. Min. Res. 10, S442.
- Glowacki, J., Connolly, M., Yeh, J., Sledge, C. B., Goloring, S. R., Girasole, G., Jilka, R., and Manolagas, S. (1994).Orthop. Trans. 18, 406.
- Cohen-Solal, M. E., Graulet, A. M., Geuris, J., Denne, M. A., Bergot, C., Morieux, C., Sedel, L., Kuntz, D., and DeVerneyoul, M. C. (1995).J. Bone Min. Res. 10, 307–314. CrossRef
- Bismar, H., Diel, I., Ziegler, R., and Pfeilschifter, J. (1995).J. Clin. Endo. Metab. 80, 3351–3355. CrossRef
- Flanagan, A. M., Horton, M. A., Dorey, E. L., Collins, D. A., Evely, R. S., Moslley, J. M., Firkin, F. C., Chambers, T. J., Helfrich, M. H., and Martin, T. J. (1992).Int. J. Exp. Path. 73, 387–401.
- Cheng, S. L., Yang, J. W., Rifas, L., Zhang, S. F., and Avioli, L. V. (1994).Endocrin. 134, 277–286. CrossRef
- Gartner, S. and Kaplan, H. S. (1980).Proc. Natl. Acad. Sci. USA 77, 4756–4759. CrossRef
- Effects of age and estrogen status on the skeletal IGF regulatory system
Volume 7, Issue 1 , pp 77-80
- Cover Date
- Print ISSN
- Online ISSN
- Humana Press
- Additional Links
- in vitro
- Industry Sectors